1
|
Horvais V, Beurrier P, Cussac V, Pan-Petesch B, Schirr-Bonnans S, Rose J, Bayart S, Ternisien C, Fouassier M, Sigaud M, Babuty A, Drillaud N, Guillet B, Trossaërt M. Key Drivers of Coagulation Factor Use in Von Willebrand Disease During Hospitalization: An Overview of the French BERHLINGO Cohort. Clin Drug Investig 2024; 44:35-49. [PMID: 38036930 DOI: 10.1007/s40261-023-01323-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 10/29/2023] [Indexed: 12/02/2023]
Abstract
BACKGROUND Von Willebrand disease (VWD) is the most common inherited bleeding disorder. However, studies of hospitalisation patterns with replacement treatment are scarce. OBJECTIVES The aim of this study was to investigate the current therapeutic management of VWD and determine the key drivers of coagulation factor uses in patients during hospitalisation. METHODS Hopscotch-WILL was a multi-centric retrospective study conducted over a 48-month period in any patients with VWD. The data were collected from the BERHLINGO Research Database and the French Hospital database. RESULTS A total of 988 patients were included; 153 patients (15%) were hospitalised during 293 stays requiring treatment with von Willebrand factor (VWF) concentrates-pure or in association with Factor VIII (FVIII). Their median basal concentrations of VWF and FVIII were significantly lower than in untreated patients: VWF antigen < 30 IU/dL, VWF activity < 20 IU/dL and FVIII:C < 40 IU/dL. The median (interquartile range) concentrate consumption was similar between highly purified VWF or VWF combined with FVIII (72 [110] vs 57 [89] IU/kg/stay, p = 0.154). The use of VWF was highly heterogeneous by VWD type; type 3 had a particularly high impact on VWF consumption in non-surgical situations. The main admissions were for ear/nose/throat, hepato-gastroenterology, and trauma/orthopaedic conditions, besides gynaecological-obstetric causes in women. CONCLUSIONS The use of VWF concentrates is mostly influenced by low basal levels of VWF and FVIII, but also by VWD type or the cause for hospitalisation. These results could inform future studies of newly released recombinant VWF.
Collapse
Affiliation(s)
- Valérie Horvais
- Nantes Université, CHU Nantes, Unité d'Investigation Clinique 17, 44000, Nantes, France.
- Nantes Université, CHU Nantes, Centre de Ressources et de Compétences des Maladies Hémorragiques Constitutionnelles, 44000, Nantes, France.
| | - Philippe Beurrier
- CHU Angers, Centre de Traitement des Maladies Hémorragiques Constitutionnelles, 49000, Angers, France
| | - Vincent Cussac
- CH Le Mans, Centre de Traitement des Maladies Hémorragiques Constitutionnelles, 72000, Le Mans, France
| | | | - Solène Schirr-Bonnans
- Nantes Université, CHU Nantes, Service Evaluation Economique et Développement des Produits de Santé, 44000, Nantes, France
| | - Johann Rose
- CH Le Mans, Centre de Traitement des Maladies Hémorragiques Constitutionnelles, 72000, Le Mans, France
| | - Sophie Bayart
- Rennes Université, CHU Rennes, Centre de Ressources et de Compétences des Maladies Hémorragiques Constitutionnelles, 35000, Rennes, France
| | - Catherine Ternisien
- Nantes Université, CHU Nantes, Centre de Ressources et de Compétences des Maladies Hémorragiques Constitutionnelles, 44000, Nantes, France
| | - Marc Fouassier
- Nantes Université, CHU Nantes, Centre de Ressources et de Compétences des Maladies Hémorragiques Constitutionnelles, 44000, Nantes, France
| | - Marianne Sigaud
- Nantes Université, CHU Nantes, Centre de Ressources et de Compétences des Maladies Hémorragiques Constitutionnelles, 44000, Nantes, France
| | - Antoine Babuty
- Nantes Université, CHU Nantes, Centre de Ressources et de Compétences des Maladies Hémorragiques Constitutionnelles, 44000, Nantes, France
| | - Nicolas Drillaud
- Nantes Université, CHU Nantes, Centre de Ressources et de Compétences des Maladies Hémorragiques Constitutionnelles, 44000, Nantes, France
| | - Benoît Guillet
- Rennes Université, CHU Rennes, Centre de Ressources et de Compétences des Maladies Hémorragiques Constitutionnelles, 35000, Rennes, France
- Inserm, EHESP, IRSET (Institut de recherche en santé, environnement et travail)-UMR_S 1085, F-35000, Rennes, France
| | - Marc Trossaërt
- Nantes Université, CHU Nantes, Centre de Ressources et de Compétences des Maladies Hémorragiques Constitutionnelles, 44000, Nantes, France
| |
Collapse
|
2
|
Drillaud N, Cussac V, Bertho PO, Horvais V, Beurrier P, Ternisien C, Rose J, Fouassier M, Babuty A, Trossaërt M. Efficacy and safety of turoctocog alfa in patients with hemophilia A requiring surgical procedures: A multicentre retrospective study. Transfusion 2023; 63:2321-2327. [PMID: 37850587 DOI: 10.1111/trf.17576] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/20/2023] [Revised: 07/24/2023] [Accepted: 09/27/2023] [Indexed: 10/19/2023]
Abstract
BACKGROUND Turoctocog alfa is a recombinant Factor VIII used in patients with hemophilia A. The aim is to assess the real-life evidence of turoctocog alfa in surgery. STUDY DESIGN AND METHODS Data were extracted from a national database. RESULTS Turoctocog alfa was used for 86 surgeries (49 major and 37 minor) in 56 patients. The results are expressed as medians (interquartile range). Six (10.7%) patients had severe hemophilia A, four (7.1%) moderate, and 46 (82.2%) mild. For patients who underwent major surgeries, basal plasma FVIII coagulant activity (FVIII:C) levels were 15 IU.dL-1 (8-22). Eight (5-14) infusions were given, at a preoperative loading dose of 40.0 (35.0-45.5) IU.kg-1 and a total dose of 253.3 (125.0-507.0) IU.kg-1 . In patients who underwent minor surgeries, basal FVIII:C levels were 18 IU.dL-1 (9-31). Two (1-3) infusions were required, at a preoperative loading dose of 34.0 (28.8-38.5) IU.kg-1 and a total dose of 73.7 (37.6-122.1) IU.kg-1 . The overall clinical efficacy was judged excellent/good in 77 procedures (89.5%) and fair/poor in nine (10.5%). The fair/poor efficacy concerned seven patients (six mild hemophilia and one severe), for four urological surgeries, two dermatological procedures, one heart surgery, one ear-nose-throat procedure, and one dental avulsion in the patient with severe hemophilia. Three out of those seven patients received antiplatelet therapy. No thromboembolic events, anti-FVIII antibodies, or adverse events were reported. DISCUSSION The efficacy and safety of turoctocog alfa were confirmed for the management of surgery in patients with hemophilia A. No adverse events were observed and overall efficacy was good.
Collapse
Affiliation(s)
- Nicolas Drillaud
- CHU Nantes, Centre de Ressources et de Compétences des Maladies Hémorragiques Constitutionnelles, Nantes Université, Nantes, France
| | - Vincent Cussac
- Centre de Traitement des Maladies Hémorragiques Constitutionnelles, CH Le Mans, Le Mans, France
| | - Pierre-Olivier Bertho
- CHU Nantes, Centre de Ressources et de Compétences des Maladies Hémorragiques Constitutionnelles, Nantes Université, Nantes, France
| | - Valérie Horvais
- CHU Nantes, Unité d'Investigation Clinique 17, Nantes Université, Nantes, France
| | - Philippe Beurrier
- Centre de Traitement des Maladies Hémorragiques Constitutionnelles, CHU Angers, Angers, France
| | - Catherine Ternisien
- CHU Nantes, Centre de Ressources et de Compétences des Maladies Hémorragiques Constitutionnelles, Nantes Université, Nantes, France
| | - Johann Rose
- Centre de Traitement des Maladies Hémorragiques Constitutionnelles, CH Le Mans, Le Mans, France
| | - Marc Fouassier
- CHU Nantes, Centre de Ressources et de Compétences des Maladies Hémorragiques Constitutionnelles, Nantes Université, Nantes, France
| | - Antoine Babuty
- CHU Nantes, Centre de Ressources et de Compétences des Maladies Hémorragiques Constitutionnelles, Nantes Université, Nantes, France
| | - Marc Trossaërt
- CHU Nantes, Centre de Ressources et de Compétences des Maladies Hémorragiques Constitutionnelles, Nantes Université, Nantes, France
| |
Collapse
|
3
|
Babuty A, Debord C, Drillaud N, Eveillard M, Trossaert M, Ternisien C, Sigaud M, Cador E, Béné MC, Fouassier M. Prothrombin consumption as an indicator of hemorrhagic phenotype in mild platelet function disorders. Eur J Haematol 2023; 111:787-795. [PMID: 37553915 DOI: 10.1111/ejh.14079] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/17/2023] [Revised: 07/28/2023] [Accepted: 07/31/2023] [Indexed: 08/10/2023]
Abstract
BACKGROUND The bleeding risk of patients with mild platelet function disorders is difficult to assess and their phenotype remains ill-explored. AIM This study was designed to establish a comprehensive biological phenotype of patients with mild platelet function disorders. METHODS Twenty patients were included with persistent abnormal light transmission aggregometry (LTA). The ISTH bleeding assessment tool (ISTH-BAT) was assessed to identify laboratory analyses associated with an abnormal hemorrhagic score. RESULTS The majority of patients had defects that might affect Gαi protein signaling pathways or minor abnormalities. No LTA nor flow cytometry parameters were associated with an above-normal hemorrhagic score. However, prothrombin consumption, which corresponds to the ratio of serum residual factor II to plasma residual factor II, was significantly higher (p = .006) in the abnormal ISTH-BAT group (mean = 14%, SD = 6) compared with the normal ISTH-BAT group (mean = 8%, SD 4). Prothrombin consumption was significantly associated with ISTH-BAT score (r = .5287, IC 95% 0.0986-0.7924, p = .0165). CONCLUSION In this group of patients, there was an association between a pathological bleeding score and increased prothrombin consumption. This test could be used as an additional indicator of platelet function abnormality liable to be related to bleeding risk.
Collapse
Affiliation(s)
- Antoine Babuty
- Nantes Université, CHU Nantes, Service d'Hématologie Biologique, Nantes, France
- Nantes Université, CHU Nantes, Centre de Ressource et de Compétence-Maladies Hémorragiques Constitutionnelles, Nantes, France
| | - Camille Debord
- Nantes Université, CHU Nantes, Service d'Hématologie Biologique, Nantes, France
| | - Nicolas Drillaud
- Nantes Université, CHU Nantes, Service d'Hématologie Biologique, Nantes, France
- Nantes Université, CHU Nantes, Centre de Ressource et de Compétence-Maladies Hémorragiques Constitutionnelles, Nantes, France
| | - Marion Eveillard
- Nantes Université, CHU Nantes, Service d'Hématologie Biologique, Nantes, France
| | - Marc Trossaert
- Nantes Université, CHU Nantes, Service d'Hématologie Biologique, Nantes, France
- Nantes Université, CHU Nantes, Centre de Ressource et de Compétence-Maladies Hémorragiques Constitutionnelles, Nantes, France
| | - Catherine Ternisien
- Nantes Université, CHU Nantes, Service d'Hématologie Biologique, Nantes, France
- Nantes Université, CHU Nantes, Centre de Ressource et de Compétence-Maladies Hémorragiques Constitutionnelles, Nantes, France
| | - Marianne Sigaud
- Nantes Université, CHU Nantes, Service d'Hématologie Biologique, Nantes, France
- Nantes Université, CHU Nantes, Centre de Ressource et de Compétence-Maladies Hémorragiques Constitutionnelles, Nantes, France
| | - Emmanuelle Cador
- Nantes Université, CHU Nantes, Service d'Hématologie Biologique, Nantes, France
| | - Marie C Béné
- Nantes Université, CHU Nantes, Service d'Hématologie Biologique, Nantes, France
| | - Marc Fouassier
- Nantes Université, CHU Nantes, Service d'Hématologie Biologique, Nantes, France
- Nantes Université, CHU Nantes, Centre de Ressource et de Compétence-Maladies Hémorragiques Constitutionnelles, Nantes, France
| |
Collapse
|
4
|
Antoine B, Boisseau P, Drillaud N, Eveillard M, Fouassier M. MYH9-related disease: Assessment of the pathogenicity of a new mutation. EJHaem 2023; 4:869-871. [PMID: 37601883 PMCID: PMC10435689 DOI: 10.1002/jha2.715] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/20/2023] [Revised: 05/07/2023] [Accepted: 05/12/2023] [Indexed: 08/22/2023]
Affiliation(s)
- Babuty Antoine
- Nantes UniversitéCHU Nantes, Service d'Hématologie BiologiqueNantesFrance
- Nantes UniversitéCHU NantesCentre de Ressource et de Compétence—MaladiesHémorragiques ConstitutionnellesNantesFrance
- Nantes UniversitéCNRS 6286 UFR Sciences et Techniques 2NantesFrance
| | - Pierre Boisseau
- Nantes Université CHU NantesService de Génétique MédicaleNantesFrance
| | - Nicolas Drillaud
- Nantes UniversitéCHU Nantes, Service d'Hématologie BiologiqueNantesFrance
- Nantes UniversitéCHU NantesCentre de Ressource et de Compétence—MaladiesHémorragiques ConstitutionnellesNantesFrance
| | - Marion Eveillard
- Nantes UniversitéCHU Nantes, Service d'Hématologie BiologiqueNantesFrance
- Nantes UniversitéINSERM UMR 1307CNRS 6075Université d'AngersCRCI2NANantesFrance
| | - Marc Fouassier
- Nantes UniversitéCHU Nantes, Service d'Hématologie BiologiqueNantesFrance
- Nantes UniversitéCHU NantesCentre de Ressource et de Compétence—MaladiesHémorragiques ConstitutionnellesNantesFrance
| |
Collapse
|
5
|
Hugon-Rodin J, Carrière C, Claeyssens S, Trillot N, Drillaud N, Biron-Andreani C, Lavenu-Bombled C, Wieland A, Flaujac C, Stieltjes N, Lebreton A, Brungs T, Hegglin A, Fiore M, Desconclois C, Gay V, Tardy-Poncet B, Beurrier P, Barbay V, Chamouni P, De Maistre E, Simurda T, Casini A. Obstetrical complications in hereditary fibrinogen disorders: the Fibrinogest Study. J Thromb Haemost 2023:S1538-7836(23)00396-3. [PMID: 37172732 DOI: 10.1016/j.jtha.2023.04.035] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/20/2023] [Revised: 04/19/2023] [Accepted: 04/27/2023] [Indexed: 05/15/2023]
Abstract
BACKGROUND Women with hereditary fibrinogen disorders (HFDs) seem to be at increased risk of adverse obstetrical outcomes, but epidemiologic data are limited Patients/methods: We conducted a retrospective and prospective international study to determine the prevalence of pregnancy complications, the modalities and management of delivery, and the postpartum events. RESULTS A total of 425 pregnancies were investigated from 159 women (49 hypofibrinogenemia, 95 dysfibrinogenemia, 15 hypodysfibrinogenemia). Overall, only 55 (12.9%) pregnancies resulted in an early miscarriage, 3 (0.7%) in a late miscarriage and 4 (0.9%) in an intrauterine fetal death. Prevalence of live birth was similar among the types of HFD (p=0.31). Obstetrical complications were observed in 54 (17.3%) of live birth pregnancies, including vaginal bleeding (14, 4.4%), retroplacental hematoma (13, 4.1%), and thrombosis (4, 1.3%). Most 56deliveries were spontaneous (218, 74.1%) with a vaginal non-instrumental delivery (195, 63.3%). A neuraxial anesthesia was performed in 116 (40.4%) pregnancies, while 71 (16.6%) and 129 (44.9%) were under general or no anesthesia, respectively. A fibrinogen infusion was administered in 28 (8.9%) deliveries. Postpartum hemorrhages were observed in 62 (19.9%) of pregnancies. Postpartum venous thrombotic events occurred in 5 (1.6%) pregnancies. Women with hypofibrinogenemia were more at risk of bleeding during the pregnancy (p=0.04). CONCLUSIONS Compared to European epidemiologic data, we did not observe a greater frequency of miscarriage while retroplacental hematoma, postpartum hemorrhage and thrombosis were more frequent. Delivery was often performed without locoregional anesthesia. Our findings highlight the urgent need for guidance on management of pregnancy in HFDs.
Collapse
Affiliation(s)
- Justine Hugon-Rodin
- Gynecology department, Gynecological Endocrinology Unit, Hospital Saint Joseph, INSERM UMR 1153, EPOPE group Paris, France; University Hospitals of Geneva and the Faculty of medicine of the Geneva University, DFEA-Ob/Gyn-reproductive medicine, Geneva, Switzerland
| | | | | | - Nathalie Trillot
- Department of Hemostasis and Transfusion, CHU Lille, Lille, France
| | - Nicolas Drillaud
- Haemophilia Treatment Centre, University Hospital, Nantes, France
| | | | - Cécile Lavenu-Bombled
- Service d'hématologie biologique, Centre de Ressources et Compétences Maladies Constitutionnelles rares, CHU Bicêtre, AP-HP, Paris, France; Université Paris-Saclay, Faculty of Medicine, Paris, France; UMR S1176 INSERM, Le Kremlin-Bicêtre, Paris, France
| | - Anna Wieland
- Department of Hematology and Central Hematology Laboratory, Bern University Hospital, University of Bern, Switzerland
| | - Claire Flaujac
- Laboratoire de biologie médicale, secteur Hémostase, Centre Hospitalier de Versailles (André Mignot), Le Chesnay, France
| | | | - Aurélien Lebreton
- Service d'hématologie, CHU Clermont-Ferrand, Clermont-Ferrand, France
| | - Thomas Brungs
- Haemostasis and Thrombosis Unit, CHR Orleans, Orleans, France
| | - Andrea Hegglin
- Luzerner Kantonsspital, Department of Hematology, Lucerne, Switzerland
| | - Mathieu Fiore
- Laboratoire d'hématologie, Hôpital cardiologique du Haut-Lévêque, CHU de Bordeaux, Bordeaux, France ; INSERMU1034, Biologie des Maladies Cardio-Vasculaires, Université de Bordeaux, Pessac, France
| | - Céline Desconclois
- Biological Hematology, Antoine Béclère Hospital, AP-HP, Paris, France; Paris-Saclay University, Clamart, France
| | - Valérie Gay
- Hemophilia Treatment Center, Hospital, Chambéry, France
| | - Brigitte Tardy-Poncet
- Centre de Ressources et de Compétence Maladies hémorragiques, CHU Saint-Etienne, Hôpital Nord, Saint-Etienne, France. Inserm, CIC 1408, Saint-Etienne, CHU Saint-Etienne Hôpital Nord, Saint-Etienne, France. Sainbiose, Inserm, U1059, Université Lyon, Saint-Etienne, France
| | - Philippe Beurrier
- Hemophilia Treatment Center, Vascular and Coagulation Clinic, University Hospital Angers, France
| | - Virginie Barbay
- Haemophilia Treatment Centre, University Hospital, Rouen, France
| | - Pierre Chamouni
- Haemophilia Treatment Centre, University Hospital, Rouen, France
| | | | - Tomas Simurda
- National Centre of Hemostasis and Thrombosis, Department of Hematology and Transfusiology, Comenius University in Bratislava, Jessenius Faculty of Medicine in Martin and University Hospital in Martin, Slovakia
| | - Alessandro Casini
- Division of angiology and hemostasis, University Hospitals of Geneva, Faculty of Medicine, Geneva, Switzerland.
| |
Collapse
|
6
|
Trossaert M, Chamouard V, Biron-Andreani C, Casini A, De Mazancourt P, De Raucourt E, Drillaud N, Frotscher B, Guillet B, Lebreton A, Roussel-Robert V, Rugeri L, Dargaud Y. Management of rare inherited bleeding disorders: Proposals of the French Reference Centre on Haemophilia and Rare Coagulation Disorders. Eur J Haematol 2023; 110:584-601. [PMID: 36748278 DOI: 10.1111/ejh.13941] [Citation(s) in RCA: 5] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/20/2022] [Revised: 01/25/2023] [Accepted: 01/31/2023] [Indexed: 02/08/2023]
Abstract
INTRODUCTION The rare coagulation disorders may present significant difficulties in diagnosis and management. In addition, considerable inter-individual variation in bleeding phenotype is observed amongst affected individuals, making the bleeding risk difficult to assess in affected individuals. The last international recommendations on rare inherited bleeding disorders (RIBDs) were published by the United Kingdom Haemophilia Centre Doctors' Organisation in 2014. Since then, new drugs have been marketed, news studies on surgery management in patients with RIBD have been published, and new orphan diseases have been described. AIM Therefore, the two main objectives of this review, based on the recent recommendations published by the French Reference Centre on Haemophilia and Rare Bleeding Disorders, are: (i) to briefly describe RIBD (clinical presentation and diagnostic work-up) to help physicians in patient screening for the early detection of such disorders; and (ii) to focus on the current management of acute haemorrhages and long term prophylaxis, surgical interventions, and pregnancy/delivery in patients with RIBD.
Collapse
Affiliation(s)
- Marc Trossaert
- Haemophilia Treatment Centre, University Hospital of Nantes and French Reference Centre on Haemophilia, Nantes, France
| | - Valerie Chamouard
- Haemophilia Treatment Centre, University Hospital of Lyon and French Reference Centre on Haemophilia, Lyon, France
| | | | - Alessandro Casini
- Angiology and Haemostasis Division, Faculty of Medicine, University Hospitals of Geneva, Geneva, Switzerland
| | - Philippe De Mazancourt
- Laboratory of Biochemistry and Molecular Genetics, Hospital Ambroise Paré-GHU APHP, Université Paris-Saclay, Boulogne-Billancourt, France
| | | | - Nicolas Drillaud
- Haemophilia Treatment Centre, University Hospital of Nantes and French Reference Centre on Haemophilia, Nantes, France
| | - Birgit Frotscher
- Haemophilia Treatment Centre, University Hospital of Nancy, Nancy, France
| | - Benoit Guillet
- Haemophilia Treatment Centre, University Hospital of Rennes, Rennes, France
| | - Aurelien Lebreton
- Haemophilia Treatment Centre, University Hospital of Clermont-Ferrand, Clermont-Ferrand, France
| | | | - Lucia Rugeri
- Haemophilia Treatment Centre, University Hospital of Lyon and French Reference Centre on Haemophilia, Lyon, France
| | - Yesim Dargaud
- Haemophilia Treatment Centre, University Hospital of Lyon and French Reference Centre on Haemophilia, Lyon, France
| |
Collapse
|
7
|
Dib F, Quéméner A, Bayart S, Boisseau P, Babuty A, Trossaërt M, Sigaud M, Ternisien C, Drillaud N, Eveillard M, Guillet B, Béné MC, Fouassier M. Biological, clinical features and modelling of heterozygous variants of glycoprotein Ib platelet subunit alpha (GP1BA) and glycoprotein Ib platelet subunit beta (GP1BB) genes responsible for constitutional thrombocytopenia. Br J Haematol 2022; 199:744-753. [PMID: 36173017 DOI: 10.1111/bjh.18462] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/04/2022] [Revised: 08/29/2022] [Accepted: 08/31/2022] [Indexed: 11/28/2022]
Abstract
Constitutional thrombocytopenias are rare disorders, often difficult to discriminate from acquired thrombocytopenias. More than 80 genes have been described as being at the origin of these diseases. Among them, several variants of the glycoprotein Ib platelet subunit alpha (GP1BA) and glycoprotein Ib platelet subunit beta (GP1BB) genes, coding for the GpIb-IX-V glycoprotein complex, have been reported in the literature. The study reported here aimed at describing newly identified monoallelic anomalies affecting the GP1BA and GP1BB genes on a clinical, biological and molecular level. In a cohort of nine patients with macrothrombocytopenia, eight heterozygous variants of the GP1BA or GP1BB genes were identified. Five of them had never been described in the heterozygous state. Computer modelling disclosed structure/function relationships of these five variants.
Collapse
Affiliation(s)
- Fatema Dib
- Service d'Hématologie Biologique, CHU de Nantes, Nantes, France
| | - Agnès Quéméner
- Nantes Université, Inserm UMR 1307, CNRS UMR 6075, Université d'Angers, CRCI2NA, Nantes, France
| | | | - Pierre Boisseau
- Service de Génétique Médicale, CHU de Nantes, Nantes, France
| | - Antoine Babuty
- Service d'Hématologie Biologique, CHU de Nantes, Nantes, France.,CRC-MH, CHU de Nantes, Nantes, France
| | - Marc Trossaërt
- Service d'Hématologie Biologique, CHU de Nantes, Nantes, France.,CRC-MH, CHU de Nantes, Nantes, France
| | - Marianne Sigaud
- Service d'Hématologie Biologique, CHU de Nantes, Nantes, France.,CRC-MH, CHU de Nantes, Nantes, France
| | - Catherine Ternisien
- Service d'Hématologie Biologique, CHU de Nantes, Nantes, France.,CRC-MH, CHU de Nantes, Nantes, France
| | - Nicolas Drillaud
- Service d'Hématologie Biologique, CHU de Nantes, Nantes, France.,CRC-MH, CHU de Nantes, Nantes, France
| | - Marion Eveillard
- Service d'Hématologie Biologique, CHU de Nantes, Nantes, France.,Nantes Université, Inserm UMR 1307, CNRS UMR 6075, Université d'Angers, CRCI2NA, Nantes, France
| | - Benoit Guillet
- CRC-MH, CHU de Rennes, Rennes, France.,Univ Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail) - UMR_S 1085, Rennes, France
| | - Marie C Béné
- Service d'Hématologie Biologique, CHU de Nantes, Nantes, France.,Nantes Université, Inserm UMR 1307, CNRS UMR 6075, Université d'Angers, CRCI2NA, Nantes, France
| | - Marc Fouassier
- Service d'Hématologie Biologique, CHU de Nantes, Nantes, France.,CRC-MH, CHU de Nantes, Nantes, France
| |
Collapse
|
8
|
Bonnard G, Babuty A, Collot R, Costes D, Drillaud N, Eveillard M, Néel A, Espitia A, Masseau A, Wahbi A, Hamidou M, Béné MC, Fouassier M. Platelet features allow to differentiate immune thrombocytopenia from inherited thrombocytopenia. Ann Hematol 2021; 100:2677-2682. [PMID: 34519886 DOI: 10.1007/s00277-021-04651-4] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/13/2021] [Accepted: 08/18/2021] [Indexed: 11/26/2022]
Abstract
Immune thrombocytopenia (ITP) is an acquired bleeding disorder, for which no specific diagnostic test exists. Inherited thrombocytopenia (IT) can mimic ITP and lead to unappropriated management with significant morbidity. Here, in small cohorts of these two disorders, we explored whether platelet sialylation and platelet activation could allow to discriminate the two conditions. We also aimed to confirm the value of immature platelet counts in this discrimination. Platelet sialylation and the expression level of P-selectin were assessed by multiparameter flow cytometry. Immature platelets were estimated on a Sysmex XN 9000 analyzer. No significant difference in platelet sialylation was observed between ITP and IT. Contrarily, platelet activation was significantly higher in ITP patients (p = 0.008). The immature platelet fraction, as previously demonstrated, was significantly lower in the ITP group compared to the IT group (p = 0.014). That statistical significance was achieved in this small pilot study suggests that the two easily available assays of immature platelet count and P-selectin expression could help physicians to reach the proper diagnosis in complex cases of thrombocytopenia.
Collapse
Affiliation(s)
- Guillaume Bonnard
- Service d'Hématologie Biologique, Hôtel Dieu, CHU de Nantes, Nantes, France.
- Centre de ressources et de compétences-Maladies hémorragiques constitutionnelles, CHU de Nantes, Nantes, France.
- Service de Médecine Interne, Hôtel Dieu, CHU de Nantes, Nantes, France.
| | - Antoine Babuty
- Service d'Hématologie Biologique, Hôtel Dieu, CHU de Nantes, Nantes, France
- Centre de ressources et de compétences-Maladies hémorragiques constitutionnelles, CHU de Nantes, Nantes, France
| | - Romain Collot
- Service D'Hématologie Clinique, Hôtel Dieu, CHU de Nantes, Nantes, France
| | - Domitille Costes
- Service D'Hématologie Clinique, Hôtel Dieu, CHU de Nantes, Nantes, France
| | - Nicolas Drillaud
- Service d'Hématologie Biologique, Hôtel Dieu, CHU de Nantes, Nantes, France
- Centre de ressources et de compétences-Maladies hémorragiques constitutionnelles, CHU de Nantes, Nantes, France
| | - Marion Eveillard
- Service d'Hématologie Biologique, Hôtel Dieu, CHU de Nantes, Nantes, France
| | - Antoine Néel
- Service de Médecine Interne, Hôtel Dieu, CHU de Nantes, Nantes, France
| | - Alexandra Espitia
- Service de Médecine Interne, Hôtel Dieu, CHU de Nantes, Nantes, France
| | - Agathe Masseau
- Service de Médecine Interne, Hôtel Dieu, CHU de Nantes, Nantes, France
| | - Anaïs Wahbi
- Service de Médecine Interne, Hôtel Dieu, CHU de Nantes, Nantes, France
| | - Mohamed Hamidou
- Service de Médecine Interne, Hôtel Dieu, CHU de Nantes, Nantes, France
| | - Marie C Béné
- Service d'Hématologie Biologique, Hôtel Dieu, CHU de Nantes, Nantes, France
- Centre de ressources et de compétences-Maladies hémorragiques constitutionnelles, CHU de Nantes, Nantes, France
| | - Marc Fouassier
- Service d'Hématologie Biologique, Hôtel Dieu, CHU de Nantes, Nantes, France
- Centre de ressources et de compétences-Maladies hémorragiques constitutionnelles, CHU de Nantes, Nantes, France
| |
Collapse
|
9
|
Mesnard B, Drillaud N, Sigaud M, Hakim G, Chelly S, Ternisien C, Fouassier M, Chelghaf I, De Vergie S, Perrouin Verbe MA, Rigaud J, David A, Trossaërt M, Branchereau J. Prostate interventions in patients with mild haemophilia: Safe and feasible. Haemophilia 2021; 27:e659-e666. [PMID: 34342928 DOI: 10.1111/hae.14388] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/26/2021] [Revised: 07/15/2021] [Accepted: 07/16/2021] [Indexed: 11/29/2022]
Abstract
INTRODUCTION To date, there is no specific recommendation or evaluation of the morbidity of prostate surgery in patients with haemophilia (PWH) although this surgery is common and at high risk of bleeding. AIM To assess the post-operative morbidity of benign prostate hyperplasia (BPH) surgeries and of oncological prostate interventions in patients with mild haemophilia A or B. METHODS We performed a monocentre, epidemiological, in real life study. Data were collected between 1 January, 1997 and 1 September, 2020 and focused on prostate biopsy, radical prostatectomy, prostate radiotherapy, simple prostatectomy, transurethral resection of prostate (TURP) and laser-vaporisation in patients with mild haemophilia A or B. RESULTS Between 1 January, 1997 and 1 September, 2020, 51 interventions were performed on 30 patients with mild haemophilia. Haemophilia A represented 93.33% of the population and haemophilia B 6.67%. For prostate biopsies (n = 24), median length of hospitalisation was 4 days and only one patient needed a blood transfusion. No patient needed re-admission. For prostatectomy (n = 10), one patient presented with intra-operative and post-operative bleeding. Two patients required re-admission. The other patients did not present any significant haemorrhagic symptoms. For radiotherapy (n = 4), two patients presented a grade II complication (radiocystitis and radiorectitis). For BPH surgeries, during hospitalisation, laser-vaporisation (n = 5) was less haemorrhagic than TURP (n = 5) but after hospital discharge, 60% of patients presented a haemorrhagic complication with two readmissions and one surgical re-explorations. CONCLUSION Performed in a specialised centre, prostate surgeries and interventions in patients with mild haemophilia is feasible with acceptable morbidity.
Collapse
Affiliation(s)
- Benoit Mesnard
- Department of Urology and Transplantation Surgery, Nantes University Hospital, Nantes, France
| | | | - Marianne Sigaud
- Haemophilia Centre, Nantes University Hospital, Nantes, France
| | - Gabriella Hakim
- Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK
| | - Samuel Chelly
- Department of Urology, Angers University Hospital, Angers, France
| | | | - Marc Fouassier
- Haemophilia Centre, Nantes University Hospital, Nantes, France
| | - Ismaël Chelghaf
- Department of Urology and Transplantation Surgery, Nantes University Hospital, Nantes, France
| | - Stéphane De Vergie
- Department of Urology and Transplantation Surgery, Nantes University Hospital, Nantes, France
| | | | - Jérôme Rigaud
- Department of Urology and Transplantation Surgery, Nantes University Hospital, Nantes, France
| | - Arthur David
- Department of Radiology, Nantes University Hospital, Nantes, France
| | - Marc Trossaërt
- Haemophilia Centre, Nantes University Hospital, Nantes, France
| | - Julien Branchereau
- Department of Urology and Transplantation Surgery, Nantes University Hospital, Nantes, France.,Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK.,Centre de Recherche en Transplantation et Immunologie CRTI Inserm, Nantes University, Nantes, France
| |
Collapse
|
10
|
Desprez D, Drillaud N, Flaujac C, Volot F, Pan-Petesch B, Beurrier P, Cussac V, Feugeas O, Pailler Y, Callegarin A, Trossaërt M, de Raucourt E. Efficacy and safety of a recombinant Von Willebrand Factor treatment in patients with inherited Von Willebrand Disease requiring surgical procedures. Haemophilia 2021; 27:270-276. [PMID: 33550648 DOI: 10.1111/hae.14242] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/26/2020] [Revised: 12/11/2020] [Accepted: 12/15/2020] [Indexed: 01/19/2023]
Abstract
INTRODUCTION Von Willebrand Disease is a common inherited haemorrhagic disorder due to a deficiency of Von Willebrand Factor (VWF). In case of surgical procedures in patients who are not responsive or have contraindications to desmopressin, replacement therapy with VWF concentrates is indicated. Until recently, only plasma-derived VWF concentrates were available. A new recombinant VWF (rVWF) concentrate that contains no Factor VIII (FVIII) but a high amount of high molecular weight VWF multimers has been available in France since 2018. AIM Describe real-world experience of using rVWF in surgical procedures. METHODS Sixty-three surgeries for 55 patients were retrospectively analysed in 7 French haemostasis centres. RESULTS During minor surgeries, the median (range) number of infusions was 1 (1-8) with a preoperative loading dose of 35 (19-56) rVWF IU/kg and a total median dose of 37.5 IU (12-288). During major surgeries, the median (range) number of infusions was only 3 (1-14) with a median preoperative loading dose of 36 IU (12-51) rVWF IU/kg, and a total median dose of 108 IU (22-340) rVWF IU/kg. The overall clinical efficacy was qualified as excellent/good in 61 of the procedures (97%), moderate in 1 (1.5%) and poor in 1 (1.5%). There was no accumulation of VWF or FVIII during postoperative monitoring. No thromboembolic events, anti-VWF antibodies or adverse events were reported. CONCLUSION This French 'real-world' experience shows that a few infusions and low doses of rVWF provided effective prevention of bleeding in major and minor surgeries in inherited VWD, with no clinically significant safety concerns.
Collapse
Affiliation(s)
- Dominique Desprez
- Department of Haemostasis, Strasbourg University Hospital, Strasbourg, France
| | - Nicolas Drillaud
- Department of Haemostasis, Nantes University Hospital, Nantes, France
| | - Claire Flaujac
- Department of Haemostasis, Versailles Hospital, Versailles, France
| | - Fabienne Volot
- Department of Haemostasis, Dijon University Hospital, Dijon, France
| | | | - Philippe Beurrier
- Department of Haemostasis, Angers University Hospital, Angers, France
| | - Vincent Cussac
- Department of Haemostasis, Le Mans Hospital, Le Mans, France
| | - Olivier Feugeas
- Department of Haemostasis, Strasbourg University Hospital, Strasbourg, France
| | - Yoann Pailler
- Department of Haemostasis, Nantes University Hospital, Nantes, France
| | | | - Marc Trossaërt
- Department of Haemostasis, Nantes University Hospital, Nantes, France
| | | |
Collapse
|
11
|
Drillaud N, Babuty A, Rugeri L, Fouassier M, Lienhart A, Béné M, Lefranc C, Ternisien C, Chamouard V, Sigaud M, Pennetier M, Trossaërt M, Meunier S. Management of previously untreated patients with severe haemophilia A preferentially treated with recombinant factor VIII products: Two French centres' real‐life experience. Haemophilia 2020; 26:e349-e352. [DOI: 10.1111/hae.14132] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/30/2020] [Revised: 07/30/2020] [Accepted: 07/30/2020] [Indexed: 11/28/2022]
Affiliation(s)
| | - Antoine Babuty
- Haemophilia Treatment Center University Hospital Nantes France
| | - Lucia Rugeri
- Haemophilia Treatment Center University Hospital Lyon France
| | - Marc Fouassier
- Haemophilia Treatment Center University Hospital Nantes France
| | - Anne Lienhart
- Haemophilia Treatment Center University Hospital Lyon France
| | - Marie‐C Béné
- Haemophilia Treatment Center University Hospital Nantes France
| | - Carole Lefranc
- Haemophilia Treatment Center University Hospital Lyon France
| | | | | | - Marianne Sigaud
- Haemophilia Treatment Center University Hospital Nantes France
| | | | - Marc Trossaërt
- Haemophilia Treatment Center University Hospital Nantes France
| | | |
Collapse
|
12
|
Trossaërt M, Flaujac C, Jeanpierre E, Drillaud N, Sigaud M, Fouassier M, Ternisien C, de Raucourt E. Assessment of primary haemostasis with a new recombinant von Willebrand factor in patients with von Willebrand disease. Haemophilia 2019; 26:e44-e48. [DOI: 10.1111/hae.13916] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/21/2019] [Revised: 11/15/2019] [Accepted: 12/03/2019] [Indexed: 11/27/2022]
Affiliation(s)
- Marc Trossaërt
- Department of Haemostasis University Hospital of Nantes Nantes France
| | - Claire Flaujac
- Department of Haemostasis Hospital of Versailles Versailles France
| | | | - Nicolas Drillaud
- Department of Haemostasis University Hospital of Nantes Nantes France
| | - Marianne Sigaud
- Department of Haemostasis University Hospital of Nantes Nantes France
| | - Marc Fouassier
- Department of Haemostasis University Hospital of Nantes Nantes France
| | | | | |
Collapse
|
13
|
Chelly S, Drillaud N, Fouassier M, De Vergie S, Perrouin-Verbe M, Rigaud J, Trossaert M, Branchereau J. Évaluation de la morbidité dans le cancer de la prostate localisé des patients porteurs d’une hémophile de type A, de type B ou d’une maladie de von Willebrand. Prog Urol 2019. [DOI: 10.1016/j.purol.2019.08.253] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
14
|
De Kyvon MA, Drillaud N, Henique H, Carmier D, Beltran S, Corcia P, Bernard PL, Chandenier B, Chandenier J, Desoubeaux G. Linear Cutaneous Erythema in a Patient With Amyotrophic Lateral Sclerosis. Clin Infect Dis 2018. [DOI: 10.1093/cid/cix1050] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
| | - Nicolas Drillaud
- Parasitologie – Mycologie – Médecine tropicale, CHU de Tours, France
| | | | | | | | | | | | | | | | | |
Collapse
|
15
|
De Kyvon MA, Drillaud N, Henique H, Carmier D, Beltran S, Corcia P, Bernard PL, Chandenier B, Chandenier J, Desoubeaux G. Linear Cutaneous Erythema in a Patient With Amyotrophic Lateral Sclerosis. Clin Infect Dis 2018; 66:1636. [PMID: 32196077 DOI: 10.1093/cid/cix1045] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
| | - Nicolas Drillaud
- Parasitologie - Mycologie - Médecine tropicale, CHU de Tours, France
| | | | | | | | | | | | | | | | | |
Collapse
|
16
|
Desoubeaux G, Franck-Martel C, Caille A, Drillaud N, Lestrade Carluer de Kyvon MA, Bailly É, Chandenier J. Use of calcofluor-blue brightener for the diagnosis ofPneumocystis jiroveciipneumonia in bronchial-alveolar lavage fluids: A single-center prospective study. Med Mycol 2016; 55:295-301. [DOI: 10.1093/mmy/myw068] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2016] [Accepted: 06/25/2016] [Indexed: 11/13/2022] Open
|
17
|
Billamboz M, Mangin F, Drillaud N, Chevrin-Villette C, Banaszak-Léonard E, Len C. Micellar catalysis using a photochromic surfactant: application to the Pd-catalyzed Tsuji-Trost reaction in water. J Org Chem 2013; 79:493-500. [PMID: 24295431 DOI: 10.1021/jo401737t] [Citation(s) in RCA: 46] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
The first example of a Pd-catalyzed Tsuji-Trost reaction, applied in a photochromic micellar media under conventional heating and microwave irradiation, is reported. The surfactant activity and recycling ability were investigated and compared with those of a few commercially available surfactants. The synthetic photochromic surfactant proved to be efficient, recyclable, and versatile for Pd-catalyzed coupling reactions.
Collapse
Affiliation(s)
- Muriel Billamboz
- Université de Technologie de Compiègne , Transformation Intégrée de la Matière Renouvelable, EA 4297 UTC/ESCOM, Centre de recherche de Royallieu, BP 20529, F-60205 Compiègne Cedex, France
| | | | | | | | | | | |
Collapse
|
18
|
Drillaud N, Banaszak-Léonard E, Pezron I, Len C. Synthesis and evaluation of a photochromic surfactant for organic reactions in aqueous media. J Org Chem 2012; 77:9553-61. [PMID: 23020740 DOI: 10.1021/jo301466w] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
A novel photochromic azobenzene-based surfactant was described for organic chemistry in water. The molecule 4-butylazobenzyl-4'-triazologlucuronic acid sodium salt thus synthesized can be isomerized from its trans to its cis form reversibly in solution by simple light irradiation. That property allowed the recyclability of a model acetylation reaction performed in the surfactant media, compared to the well-known, commercially available sodium dodecyl sulfate surfactant media.
Collapse
Affiliation(s)
- Nicolas Drillaud
- Université de Technologie de Compiègne, Transformation Intégrée de la Matière Renouvelable, EA 4297 UTC/ESCOM, Centre de Recherche de Royallieu, BP 20529, F-60205 Compiègne Cedex, France
| | | | | | | |
Collapse
|
19
|
Affiliation(s)
- Marie Lopez
- Eskitis Institute, Griffith University, Brisbane, Queensland 4111, Australia
| | - Nicolas Drillaud
- Eskitis Institute, Griffith University, Brisbane, Queensland 4111, Australia
| | - Laurent F. Bornaghi
- Eskitis Institute, Griffith University, Brisbane, Queensland 4111, Australia
| | - Sally-Ann Poulsen
- Eskitis Institute, Griffith University, Brisbane, Queensland 4111, Australia
| |
Collapse
|